Innovation, Quality & Collaboration
for a Healthier World
PANDA is a multi-center, double-blind, randomized, dose-ranging clinical trial to evaluate the efficacy and safety of Conbercept intravitreal injection in the treatment of patients with neovascular age-related macular degeneration. This project was initiated by Chengdu Kanghong Biotechnology Co., Ltd., a wholly-owned subsidiary of Kanghong Pharmaceutical Group.
The purpose of this clinical study is to evaluate the efficacy and safety of two different levels of conbercept intravitreal (IVT) injection as compared to the approved vascular endothelial growth factor (VEGF) antagonist active control, aflibercept intravitreal injection (2.0 mg/eye, Eylea®), in subjects with neovascular AMD.
Neovascular Age-related Macular Degeneration
Biological: 0.5 mg Conbercept Intravitreal Injection
Biological: 1.0 mg Conbercept Intravitreal Injection
Biological: 2.0 mg Aflibercept Intravitreal Injection